Trials / No Longer Available
No Longer AvailableNCT01120561
A Study of Trastuzumab-MCC-DM1 in Patients With HER2- Positive Locally Advanced or Metastatic Breast Cancer
An Expanded Access, Open-Label Study of Trastuzumab-MCC-DM1 Administered Intravenously to Patients With HER2- Positive Locally Advanced or Metastatic Breast Cancer
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Genentech, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a multicenter, open-label, single-arm, expanded access study designed to provide T-DM1 to patients with HER2-positive locally advanced or metastatic breast cancer and to evaluate the safety and efficacy of T-DM1 administered by intravenous (IV) infusion.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | trastuzumab-MCC-DM1 | Intravenous repeating dose |
Timeline
- Start date
- 2010-05-01
- First posted
- 2010-05-11
- Last updated
- 2017-02-15
Locations
15 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01120561. Inclusion in this directory is not an endorsement.